Valuation: Axsome Therapeutics, Inc.

Market Cap 11.33B 9.78B 9.21B 8.37B 15.74B 1,085B 15.97B 108B 42.32B 543B 42.53B 41.61B 1,808B P/E 2026 *
-81.2x
P/E 2027 * 46.4x
Enterprise Value 11.17B 9.65B 9.08B 8.25B 15.52B 1,070B 15.75B 106B 41.73B 535B 41.94B 41.03B 1,783B EV / Sales 2026 *
11.5x
EV / Sales 2027 * 6.97x
Free-Float
84.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
1 week+0.22%
Current month-0.80%
1 month-2.43%
3 months-4.90%
6 months+17.06%
Current year+18.40%
1 week 208.95
Extreme 208.95
221.55
1 month 206.94
Extreme 206.94
245.5
Current year 152.28
Extreme 152.28
260.19
1 year 109.6
Extreme 109.6
260.19
3 years 55.02
Extreme 55.02
260.19
5 years 19.38
Extreme 19.38
260.19
10 years 1.94
Extreme 1.94
260.19
Manager TitleAgeSince
Chief Executive Officer 57 2012-01-11
Director of Finance/CFO 51 2018-05-15
Chief Operating Officer 42 2014-03-31
Director TitleAgeSince
Chairman 57 2012-01-11
Director/Board Member 64 2014-11-30
Director/Board Member 58 2014-11-30
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Fiscal year

Chief Executive Officer

13,980 0.0272%
7/1/26 Fiscal year

Chief Executive Officer

148,998 0.2895%
6/5/26 Free

Director

1,721 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%+0.22%+94.59%+205.52% 11.33B
+1.72%+2.80%+42.76%+0.85% 80.48B
-1.10%-2.42%-3.61%+28.98% 50.63B
+0.88%-3.93%+11.18%+169.94% 47.57B
+17.25%+17.36%-41.63%-41.46% 45.84B
+2.14%+4.68%+57.05%-18.27% 30.9B
-0.98%+5.50%+127.48%-37.12% 25.73B
+0.11%+2.40%+45.98%+93.58% 25.03B
+1.36%-0.67%-0.87%+195.57% 21.16B
+1.49%+5.26%+65.34%+127.30% 16.75B
Average +2.27%-0.14%+39.83%+72.49% 35.54B
Weighted average by Cap. +2.82%-0.66%+28.77%+48.23%

Financials

2026 *2027 *
Net sales 971M 839M 789M 717M 1.35B 93.04B 1.37B 9.26B 3.63B 46.53B 3.65B 3.57B 155B 1.56B 1.35B 1.27B 1.15B 2.17B 150B 2.2B 14.89B 5.84B 74.86B 5.87B 5.74B 249B
Net income -140M -121M -113M -103M -194M -13.38B -197M -1.33B -522M -6.69B -524M -513M -22.29B 259M 223M 210M 191M 359M 24.79B 365M 2.47B 966M 12.4B 971M 950M 41.3B
Net Debt -156M -135M -127M -116M -217M -14.99B -221M -1.49B -585M -7.5B -587M -575M -24.98B -435M -376M -354M -322M -605M -41.71B -614M -4.15B -1.63B -20.86B -1.63B -1.6B -69.49B
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
Employees
1,346
Date Price Change Volume
26-08-18 $217.10 +0.38% 131,043
26-08-17 $216.27 +1.22% 511,870
26-08-14 $213.67 -0.00% 476,327
26-08-13 $213.68 -0.46% 705,315
26-08-12 $214.66 -0.51% 1,240,601
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
216.27USD
Average target price
285.42USD
Spread / Average Target
+31.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXSM Stock